Participant flow14

How many started, completed or left each group, period by period.

1 to 14 of 14

Period	Milestone	Group	Participants
Overall Study	STARTED	Sitagliptin	153
Overall Study	STARTED	Glimepiride	152
Overall Study	Received Study Drug	Sitagliptin	148
Overall Study	Received Study Drug	Glimepiride	143
Overall Study	Continued Treatment for 12 Weeks	Sitagliptin	143
Overall Study	Continued Treatment for 12 Weeks	Glimepiride	129
Overall Study	Completed 52-week Treatment	Sitagliptin	119
Overall Study	Completed 52-week Treatment	Glimepiride	111
Overall Study	Enrolled in Extension Study	Sitagliptin	80
Overall Study	Enrolled in Extension Study	Glimepiride	61
Overall Study	COMPLETED	Sitagliptin	76
Overall Study	COMPLETED	Glimepiride	60
Overall Study	NOT COMPLETED	Sitagliptin	77
Overall Study	NOT COMPLETED	Glimepiride	92

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01183104/flow